C12N 2310/20
Involving clustered regularly interspaced short palindromic repeats [crispr]
Official title: involving clustered regularly interspaced short palindromic repeats [CRISPR]
C12N2310/20 (Involving clustered regularly interspaced short palindromic repeats [crispr]) appears on 2,683 US grants and 7,884 published applications in this corpus.
Search patents in C12N- Granted patents
- 2,683
- Published applications
- 7,884
- Assignees
- 1,703
- Inventors
- 11,890
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 9 | 30 |
| 2015 | 3 | 34 |
| 2016 | 7 | 115 |
| 2017 | 28 | 153 |
| 2018 | 58 | 396 |
| 2019 | 118 | 552 |
| 2020 | 202 | 680 |
| 2021 | 291 | 802 |
| 2022 | 364 | 940 |
| 2023 | 385 | 1027 |
| 2024 | 404 | 1213 |
| 2025 | 482 | 1102 |
| 2026 | 332 | 840 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Prime editor system for in vivo genome editing6 Oct 2026US 12,753,397 B2University of Massachusetts
- CRISPR-mediated directed codon re-write6 Oct 2026US 12,753,398 B2Limagrain Europe S.A.
- OPA1 antisense oligomers for treatment of conditions and diseases6 Oct 2026US 12,753,408 B2Stoke Therapeutics, Inc.
- Compositions and methods for modifying a target nucleic acid6 Oct 2026US 12,753,412 B2The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
- RNA guide genome editing in citrus using CRISPR-ribonucleoprotein complexes6 Oct 2026US 12,753,413 B2University of Florida Research Foundation, Inc.
- Humanized ace2-expressing transgenic mouse susceptible to sars-cov-2 virus infection and method for producing same8 Oct 2026US 2026/0305587 A1Seoul National University R&Db Foundation
- Methods of preventing on-target genotoxicity induced by nucleases8 Oct 2026US 2026/0306552 A1Chu De Bordeaux
- Base editing approaches to treat abca4-associated stargardt disease8 Oct 2026US 2026/0306670 A1Massachusetts Eye and Ear Infirmary
- Transcription factor 4 gene editing system8 Oct 2026US 2026/0306671 A1The Regents of the University of California
- Targeting gpatch8 for treating sf3b1-mutant cancers8 Oct 2026US 2026/0306672 A1Fred Hutchinson Cancer Center
Most cited
By later US patents
- CRISPR-Cas systems and methods for altering expression of gene products1,186US 8,697,359 B1Massachusetts Institute of Technology · 2014
- CRISPR-Cas component systems, methods and compositions for sequence manipulation560US 8,795,965 B2Massachusetts Institute of Technology · 2014
- CRISPR-Cas component systems, methods and compositions for sequence manipulation529US 8,871,445 B2Massachusetts Institute of Technology · 2014
- Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation489US 8,865,406 B2Massachusetts Institute of Technology · 2014
- CRISPR-Cas systems and methods for altering expression of gene products483US 8,945,839 B2Massachusetts Institute of Technology · 2015